



## Press Release

### **TxCell: monthly information regarding the total number of voting rights and the total number of shares**

**Valbonne, France, August 3, 2015 – TxCell SA (Euronext Paris: FR0010127662 – TXCL)**, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports the monthly information regarding the total number of voting rights and the total number of shares..

Pursuant to the article 223-16 of the AMF General Regulation, the total number of shares comprising the share capital and the total number of voting rights as of July 31, 2015, is presented as follow:

Date	Total number of shares of the Company	Total number of voting rights	
		Total gross (1)	Total net (2)
31/07/2015	12 883 518	12 883 518	12 874 679

- (1) Pursuant to the article 223-11 of the AMF General Regulation, the total number of gross voting rights is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The number of gross voting rights (or theoretical voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
- (2) The total number of net voting rights (or exercisable voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

**About TxCell:** [www.txcell.com](http://www.txcell.com)

TxCell develops innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary product platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave<sup>®</sup> in refractory Crohn's disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell has a strategic collaboration for the development of Ovasave with the Swiss company Trizell Holding S.A. and Ferring International Center S.A. remains the intended final commercializing party. Both companies are affiliates of the Dr Frederik Paulsen Foundation. TxCell's second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a

rare disease of the eye. Listed on the regulated market Euronext Paris, TxCell is a spin-off of Inserm (France's National Institute for Health and Medical Research). TxCell has 68 employees based both at the headquarters located in the Sophia Antipolis technology park, Nice, France and at its manufacturing site in Besançon.

#### Contacts:

##### **TxCell**

Raphaël Flipo  
CFO  
Tél: +33 4 97 218 300  
[contact@txcell.com](mailto:contact@txcell.com)

##### **NewCap – Investor relations**

Financial Communication  
Julien Perez / Pierre Laurent  
Tél: +33 1 44 71 94 94  
[txcell@newcap.fr](mailto:txcell@newcap.fr)

